We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04802343
Previous Study | Return to List | Next Study

A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04802343
Recruitment Status : Completed
First Posted : March 17, 2021
Last Update Posted : October 19, 2022
Information provided by (Responsible Party):

Brief Summary:

Researchers are looking for a better way to treat chronic cough. Before patients with medical conditions can join clinical trials, researchers do trials in healthy participants first to understand how the body acts on the new treatment and learn how safe it is.

In this trial, the researchers will study how much of the trial drug, BAY1817080, gets into the blood in a small number of participants. The trial will include about 39 healthy Chinese male who are aged 18 to 45.

For this trial participants will be divided in 3 groups. Groups 1 and 2 will take either dose 1 or dose 2 of BAY1817080 or placebo 1 time. Participants of groups 3 will take dose 3 of BAY1817080 or placebo one time at the first day and continue to take dose 3 of BAY1817080 twice a day from day 7 to day 16 of the trial. On day 17 they will take only one dose 3 of BAY1817080.

All participants will take BAY1817080 or a placebo as a tablet by mouth. For this trial, the participants in Groups 1 and 2 will stay at the trial site for up to 10 days. The participants in Group 3 will stay at the trial site for up to 26 days. The trial will last up to 4 weeks for the participants in Groups 1 and 2, and 6 weeks for the participants in Group 3.

During the trial, the doctors will take blood and urine samples and check the participants blood pressure, pulse rate and electrocardiogram (ECG). The participants will answer questions about how they are feeling to check their general wellbeing.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: BAY1817080 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: A Single-center, Randomized, Placebo-controlled, Parallel-group, Double-blind Study to Investigate the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of BAY 1817080 in Chinese Healthy Adult Male Participants.
Actual Study Start Date : April 2, 2021
Actual Primary Completion Date : July 19, 2021
Actual Study Completion Date : October 29, 2021

Arm Intervention/treatment
Experimental: BAY1817080 dose escalation
Healthy male subjects will receive BAY1817080 dose 1 and dose 2 as a single oral dose and BAY1817080 dose 3 as a single oral dose on Day 1 and twice daily (BID) from Day 7 to Day 16 followed by a last dose in the morning of Day 17.
Drug: BAY1817080
Oral, tablet.

Placebo Comparator: Placebo
Healthy male subjects will received corresponding placebo.
Drug: Placebo
Oral, tablet.

Primary Outcome Measures :
  1. Cmax of BAY1817080 dose 1 and dose 2 (Day 1) [ Time Frame: Pre-dose on Day 1 to 216 hours post-dose ]
    Cmax: maximum observed drug concentration in measured matrix after single dose administration

  2. Cmax of BAY1817080 dose 3 (Day 1) [ Time Frame: Pre-dose on Day 1 to 144 hours post-dose ]
    Cmax: maximum observed drug concentration in measured matrix after single dose administration

  3. AUC of BAY1817080 dose 1 and dose 2 (Day 1) [ Time Frame: Pre-dose on Day 1 to 216 hours post-dose ]
    AUC: area under the concentration vs. time curve

  4. AUC of BAY1817080 dose 3 (Day 1) [ Time Frame: Pre-dose on Day 1 to 144 hours post-dose ]
    AUC: area under the concentration vs. time curve

  5. Cmax,md of BAY1817080 in dose 3 cohort (Day 17) [ Time Frame: Pre-dose on Day 17 to 12 hours post-dose ]
    Cmax,md: maximum observed drug concentration in measured matrix after multiple dose administration during a dosage interval, directly taken from analytical data

  6. AUCτ,md of BAY1817080 in dose 3 cohort (Day 17) [ Time Frame: Pre-dose on Day 17 to 12 hours post-dose ]
    AUCτ,md: the area under the concentration-time curve in the dosing interval after multiple doses

Secondary Outcome Measures :
  1. Number of participants with treatment emergent adverse events (TEAEs) with intensity [ Time Frame: From the first dose of study intervention up to the follow-up visit (up to 30 days) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Participants who are overtly healthy according to complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12-Lead electrocardiogram (ECG), and clinical laboratory tests
  • Race: Chinese
  • Age: 18 to 45 years (inclusive) of age
  • Weight: Body mass index (BMI): ≥ 18.0 and <= 27.9 kg/m²
  • Male participants
  • Subjects who agree to use adequate contraception when sexually active during the study period and for 90 days after receiving the investigational medicinal product and not to act as sperm donor for 90 days after dosing.

Exclusion Criteria:

Medical and Surgical History

  • Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ECG) deviating from normal and deemed by the investigator to be of clinical relevance
  • Medical history of hypogeusia/dysgeusia or dysfunction in the ability to taste
  • Any known presence or history of severe allergies, non-allergic drug reactions, or multiple drug allergies
  • Known or suspected malignant tumors or carcinoma in situ
  • Known liver disease: existing acute or chronic progressive liver disease, e.g. disturbance of bilirubin excretion (Dubin-Johnson and Rotor syndromes); disturbances of bile secretion and flow (cholestasis); presence or history of liver tumors (benign or malignant). (Note: According to this criterion, there must have been an interval of at least 6 months between the subsidence of any viral hepatitis [normalization of liver parameters] and the screening visit.)
  • Any known relevant kidney disease (e.g. glomerulonephritis) or any renal injury associated with multisystem diseases/disorders (e.g. systemic lupus erythematosus, diabetic nephropathy)
  • Known metabolic disorders (e.g. diabetes mellitus, severe hypertriglyceridemia)
  • Known cardiovascular disorders requiring treatment
  • Migraine with neurological symptoms (complicated migraine)
  • Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
  • Known hypersensitivity to the study interventions including components of the preparation Medication, drug use and special behavioral patterns
  • Regular use of therapeutic or recreational drugs, e.g. carnitine products, anabolics, high-dose vitamins
  • Intake of drugs with a long half-life (>24 hours) within a timeframe of less than 5 half-lives before study drug administration
  • Use of any systemic or topically active drug(s) that might influence the results of the study within the 14 days before study intervention administration or during the study until follow-up. (Note: This includes drugs that might affect the PK of BAY 1817080, e.g. laxatives, loperamide, metoclopramide, antacids, H2-receptor antagonists, cytochrome P450 [CYP] 3A4 inducers, strong CYP3A4 inhibitors).

Electrocardiogram, blood pressure, pulse rate

  • Clinically relevant ECG findings, such as a second- or third-degree atrioventricular block, prolongation of the QRS complex over 120 msec at screening or pre-dose baseline measurement on Day -1 Physical examination
  • Clinically relevant findings in the physical examination Neurological examination
  • Clinically relevant findings in the orientating, basic neurological examination Laboratory examination
  • Positive result in urine drug screening, or positive alcohol breath test Other
  • Participation in another study and received an investigational drug within the 2 months or a longer and more appropriate time as determined by the investigator (e.g. approx. 5 half-lives of the previous investigational drug) before first study intervention administration
  • Criteria that in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the participant's safety

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04802343

Layout table for location information
Zhongshan Hospital, Fudan University
Shanghai, China, 200032
Sponsors and Collaborators
Additional Information:
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT04802343    
Other Study ID Numbers: 21009
First Posted: March 17, 2021    Key Record Dates
Last Update Posted: October 19, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description:

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Pharmacokinetics (PK)